Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human intrathecal ISIS 814907 in mild Alzheimer's disease
NL-OMON55789Phase 1Recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jan 2018
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of biib080 in Alzheimer's disease (AD) (3 arms), sponsored by Ionis Pharmaceuticals. Primary endpoints: Safety and tolerability and Safety monitoring measures. Started Jan 2018; status: recruiting.
02
Drugs
biib080
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON55789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55789.